DRUG · Unmapped registry intervention
TNO155
Find medicine records ·
Find other trials using this name
Clinical trial
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
NCT04000529
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Spartalizumab
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Ribociclib
Normalized identity: ribociclibView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPhase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Colorectal Cancerverified · MONDO: colorectal cancer
Interventions
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04000529 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.